• Covid-19 Sputnik V, the Russian vaccine against covid confirms an efficacy of 90%

  • Spain.Darias opens the door to the Russian vaccine Sputnik V

  • Live: last minute of the coronavirus

The main Russian vaccine looks for other formats to speed up immunization and prevent infections.

Clinical trials of the Sputnik V vaccine in the form of nasal drops are to be carried out in Moscow.

The drops are not a substitute for full vaccination, but may be useful as an additional form of protection if immune resistance declines, the duration of which is not yet clear.

"Specialists have developed a

nasal version of Sputnik V that forms immunity in the nasopharynx area

. We are exploring new ways to protect ourselves against the coronavirus," the mayor of the Russian capital Sergei Sobianin said on his blog.

According to Russian scientists have declared to the magazine 'Forbes', after an intramuscular vaccination there is the possibility that the person continues to be a carrier of the infection for some time: "It is possible that the person does not even notice the infection, but will be a carrier for some time. several days".

But if the vaccine is administered through the nose, in addition to protecting the lower respiratory tract and lungs, it will form a first line of defense with the immunity of the mucous membranes.

The big question is when this vaccine will be ready.

Industry and Trade Minister Denis Manturov said in an interview with Interfax that "clinical trials should start in April for subsequent serial production."

The

development of the intranasal format is carried out by the Gamaleya Institute

(creator of the Sputnik V vaccine) and the Generium company.

Another Russian entity, the Novosibirsk Federal Research Center for Medicine, is also on the trail of a drop vaccine, although the project is in trouble due to lack of funding.

Both teams pursue the same goal: a vaccine that prevents injection and gives additional protection to the body.

Scientists believe that in the case of a repeat vaccination, the second intramuscular injection may not be as effective as the first.

This would be because in addition to the antibodies against the coronavirus, antibodies have also been formed against the vector itself, the adenovirus, which promotes the antibodies.

The application through the nose could allow to overcome this obstacle, although the vectors are the same.

All three phases of clinical trials of the drug will take place in Moscow.

Trust in the vaccine

Half a year has passed since Russia announced that the state Gamaleya Institute was developing a coronavirus vaccine.

When Moscow announced last November that its Sputnik V vaccine was 92% effective, the news was greeted with skepticism inside and outside Russia.

Its efficacy was recently endorsed by the prestigious British medical journal 'The Lancet'.

Now the next step is to

check how long the immunity lasts.

2,000 people who received the first component of the vaccine

in the past six months will undergo an antibody test every month - from February to August.

The city council says that the study will make it possible to know if "revaccination" is necessary for the next autumn-winter epidemiological season.

Russia is also beginning clinical trials of the vaccine called Sputnik Light.

It is a new drug also developed at the Gamaleya Institute, it aims to eliminate the main drawback of the first Sputnik V: the presence of two components administered to the patient with a difference of several weeks.

"Vaccination with Sputnik Light requires only one visit to the vaccination center," the mayor said.

Four weeks after the puncture, maximum immunity would be reached.

Sputnik V tests will

also

be carried out in minors between 14 and 18 years old

, which will allow "deciding whether or not to include adolescents in the vaccination program," according to municipal sources.

According to the criteria of The Trust Project

Know more

  • Vaccines

  • Science and Health

  • Coronavirus

  • Covid 19

  • Infectious diseases

  • Respiratory diseases

Interview "As we vaccinate, we will have to watch that a variant of the coronavirus does not escape"

Israel now observes the effects of the vaccine in reducing the transmission of the coronavirus

UK makes global 'inventory' of all coronavirus mutations

See links of interest

  • Work calendar

  • Final: Novak Djokovic-Daniil Medvedev, live

  • Parma - Udinese

  • West Ham United - Tottenham Hotspur

  • FC Augsburg - Bayer 04 Leverkusen

  • Barcelona - Cádiz, live